References
1. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Pal’gova L.K., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study result. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2015; (6): 31–41. (in Rusian)
2. Trukhan D.I. Non-alcoholic fatty liver disease: therapeutic and dietary recommendations at the stage of primary health care. Meditsinskiy sovet [Medical Council]. 2015; (17): 78–84. (in Russian)
3. Chernyak O.O., Sentsova T.B., Vorozhko I.V., Tutel’yan V.A., Gapparova K.M., Isakov V.A. Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part I. Voprosy pitaniia [Problems of Nutrition]. 2015; (4): 18–24. DOI: http://doi.org/10.24411/0042-8833-2015-00030 (in Russian)
4. Ermolova T.V., Ermolov S.Yu. Nonalcoholic steatohepatitis: treatment from the standpoint of evidence-based medicine. Effektivnaya farmakoterapiya. Gastroenterologiya [Effective Pharmacotherapy. Gastroenterology]. 2011; (2): 30–4. (in Russian)
5. Masharova A.A., Danilevskaya N.N. Nonalcoholic steatohepatitis: from pathogenesis to therapy. RMZh Gastroenterologiya [ RMJ. Gastroenterology], 2013; (31): 1642–5. (in Russian)
6. Kucheryavy Yu.A., Maevskaya E.A., Akhtaeva M.L., et al. Nonalcoholic steatohepatitis and intestinal microflora: is there a potential for probiotic drugs in treatment. Meditsinskiy sovet [Medical Council]. 2013; (3): 46–51. (in Russian)
7. Kutyreva E.N., Pavlovskaya E.V., Surkov A.G., Strokova T.V., Kaganov B.S. Non-alcoholic steatohepatitis in obese children: prevalence and clinical manifestations. Voprosy dietologii [Problems of Dietology]. 2011; 1 (2): 54. (in Russian)
8. Shvarts V., Nogaller A. Non-alcoholic steatohepatitis: pathogenesis, diagnosis, treatment. Vrach [Physician]. 2011; (10): 31–5. (in Russian)
9. Andreev D.N., Maev I.V., Dicheva D.T.m et al. Diagnosis and treatment of non-alcoholic fatty liver disease: review of the 2016 European Guidelines. Consilium Medicum. 2017; 19 (8): 8–13. DOI: http://doi.org/10.26442/2075-1753_19.8.8-13 (in Russian)
10. Miller E.F. Nutrition management strategies for nonalcoholic fatty liver disease: treatment and prevention. Clin Liver Dis (Hoboken). 2020; 15 (4): 144–8. DOI: http://doi.org/10.1002/cld.918
11. Tutel’yan V.A. Chemical composition and calorific value of Russian food products: Handbook. Moscow: DeLi plyus, 2012: 284 р. (in Russian)
12. Nazarenko L.I., Petrova Yu.N., Rayhkel’son K.L., Baranovsky A.Yu. Nutritional errors in non-alcoholic fatty liver disease and ways to correct them. Eksperimental’naya i klinicheskaya gastoenterologiya [Experimental and Clinical Gastroenterology]. 2012; (2): 19–24. (in Russian)
13. Lyudinina A.Yu., Boyko E.R. Functional role of monounsaturated fatty acids in the human body. Uspekhi fiziologicheskikh nauk [Advances in the Physiological Sciences]. 2013; 44 (4): 51–64. (in Russian)
14. Qian F., Korat A.A., Malik V., et al. Metabolic effects of monounsaturated fatty acid-enriched diets compared with carbohydrate or polyunsaturated fatty acid-enriched diets in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2016; 39: 1448–57. DOI: http://doi.org/10.2337/dc16-1613
15. Yokoyama J., Someya Y., Yoshihara R., et al. Effects of high-monounsaturated fatty acid enteral formula versus high-carbohydrate enteral formula on plasma glucose concentration and insulin secretion in healthy individuals and diabetic patients. J Int Med Res. 2008; 36 (1): 137–46.
16. Albracht-Schulte K., Kalupahana N.S., Ramalingam L., et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem. 2018; 58: 1–16. DOI: http://doi.org/10.1016/j.jnutbio.2018.02.012
17. Lorente-Cebrián S., Costa A.G., Navas-Carretero S., et al. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem. 2013; 69 (3): 633–51. DOI: http://doi.org/10.1007/s13105-013-0265-4
18. Uspensky Yu.P., Balukova E.V. Non-alcoholic fatty liver disease: current perspectives of therapy. Meditsinskiy alfavit. Prakticheskaya gastroenterologiya [Medical Alphabet. Practical Gastroenterology]. 2017; 3 (27): 25–32. (in Russian)
19. Shirokova E.N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. Gastroenterologiya [Consilium Medicum. Gastroenterology]. 2017; 19 (8-2): 74–6. DOI: http://doi.org/10.26442/2075-1753_19.8.2.74-76 (in Russian)
20. Kazyulin A.N. The possibility of early prevention of progression of non-alcoholic fatty liver disease in the practice of a clinician. Farmateka [Pharmateca]. 2017; (2): 63–70. (in Russian)
21. Tokaev E.S., Manuk'yan G.V. Protein product «Heparin». Patent RU No. 2249416 C1. Publ. 10.04.2005. Bull. No. 10. (in Russian)
22. Tutel’yan V.A., Baygarin E.K., Pogozheva A.V. Dietary fiber: hygienic characteristics and assessment of the effectiveness. Moscow: SvR ARGUS, 2012: 244 р. (in Russian)
23. Kiseleva T.L., Kochetkova A.A., Tutel’yan V.A., Sharafetdinov H.H. Cereals and foods in the diet for type 2 diabetes: monograph. Moscow: BIBLIO-GLOBUS, 2018: 690 р. DOI: http://doi.org/10.18334/9785907063297 (in Russian)
24. Namazi N., Larijani B., Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018; 37 (2): 419–28. DOI: http://doi.org/10.1016/j.clnu.2017.06.002
25. Shilov A.M., Mel’nik M.V., Voevodina E.S. Coenzyme Q10 and vitamin E in the complex therapy of patients with CHF. Vrach [Physician]. 2011; (1): 49–52. (in Russian)
26. Zvyagintseva T.D., Glushchenko S.V. L-carnitine and oxidative stress – stress in non-alcoholic steatohepatitis. Gastroenterologiya [Gastroenterology]. 2015; 2 (103 pt II): 19–20. (in Russian)
27. Trukhan D.I. Role and place of L-carnitine in cytoprotection and correction of metabolic processes. Meditsinskiy sovet [Medical Council]. 2017; (12): 182–7. DOI: http://doi.org/10.21518/2079-701X-2017-12-182-187 (in Russian).
28. Mikelov V.A., Kayshev A.Sh., Kaysheva N.Sh., Nguen Hong Ha Thui. Betaines as medicines. Materialy V Vserossiyskoy nauchno-prakticheskoy konferentsii «Belikovskie chteniya» [Proceedings of the Fifth all-Russian Scientific-Practical conference «Belikov Readings»]. Pyatigorsk, 2017: 55–60. (in Russian)
29. Mukherjee S. Role of betaine in liver disease-worth revisiting or has the die been cast? World J Gastroenterol. 2020; 26 (38): 5745–8. DOI: http://doi.org/10.3748/wjg.v26.i38.5745